Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “neutral” rating restated by stock analysts at UBS AG in a research report issued on Thursday, www.flashratings.com reports. They presently have a $19.00 price target on the stock. UBS AG’s target price suggests a potential upside of 0.74% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Vetr downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 target price for the company. in a research note on Tuesday, July 4th. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Wednesday, July 5th. Wells Fargo & Company reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, June 27th. Cantor Fitzgerald set a $31.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, June 22nd. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $33.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, June 23rd. Five investment analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $32.15.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 2.55% during mid-day trading on Thursday, hitting $18.38. The stock had a trading volume of 10,131,445 shares. The stock’s market capitalization is $18.67 billion. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $52.66. The stock’s 50-day moving average price is $20.22 and its 200-day moving average price is $28.82.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter last year, the company posted $1.25 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/14/teva-pharmaceutical-industries-limited-teva-stock-rating-reaffirmed-by-ubs-ag.html.

Several large investors have recently modified their holdings of the company. San Francisco Sentry Investment Group CA acquired a new position in Teva Pharmaceutical Industries Limited in the second quarter valued at $106,000. Bronfman E.L. Rothschild L.P. lifted its holdings in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the period. Kistler Tiffany Companies LLC lifted its holdings in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares during the period. FNY Managed Accounts LLC acquired a new position in Teva Pharmaceutical Industries Limited in the first quarter valued at $123,000. Finally, Sterling Investment Advisors Ltd. lifted its holdings in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the period. Institutional investors own 56.87% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.